Lakefront Biotherapeutics NV (LKFT) stock

LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026Score 7/30

$33.98+0.05 (+0.15%)

Close on Nov 13, 2026Market cap $2.24BP/E 6.3Yield –

Lakefront Biotherapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

For fiscal 2025 it was 97.3%, against 87.4% the year before.

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	97.3%	+10.0
FY2024	Dec 31, 2024	87.4%	−7.6
FY2022	Dec 31, 2022	95.0%	−4.3
FY2021	Dec 31, 2021	99.3%	–

Parsed from the XBRL in Lakefront Biotherapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is LKFT.

Revenue growth303.5% · median 59.5%

Gross margin97.3% · median 83.6%

Operating margin26.5% · median 12.8%

Net margin28.9% · median 1.2%

Advertisement
300 × 250

See a number that looks wrong?